RSV antibody shot for babies hits obstacles in rollout: "As pediatricians, we're angry"
CBSN
RSV season is ramping up, and doctors are hoping a new shot to prevent the virus in young children will ease the caseload this year. However, some pediatricians are facing challenges getting supply.
The CDC and FDA have approved the Beyfortus antibody shot, from drugmakers AstraZeneca and Sanofi, to prevent respiratory syncytial virus in babies from birth to 8 months old, or in children up to 24 months old with severe risk factors.
RSV is the leading cause of hospital admissions in children younger than 1 year old.

The Trump administration deployed ICE and other Homeland Security agents to 14 of the nation's airports on Monday to help shuttle passengers through overcrowded TSA checkpoints. In one airport, the security line wait-time was up to six hours. Nicole Sganga and Kaia Hubbard contributed to this report. In:












